Eli Lilly and Company

Darden Business Publishing Cases

ISSN: 2474-7890

Publication date: 20 January 2017


This negotiation case is meant to be used in conjunction with “Hybritech, Incorporated (A)” (UVA-F-0792); half the class works from one case and half from the other. Lilly is considering acquiring Hybritech, but the genetic-engineering company's future cash flows are difficult to predict and value. Both companies want to effect the merger, but the cases, which provide essentially the same information in all other respects, provide widely divergent projected cash flows. The “Hybritech, Incorporated (B)” case (UVA-F-0793) is the follow-up case dealing with the payment structure of the acquisition.



Bruner, R. and Opitz, C. (2017), "Eli Lilly and Company", Darden Business Publishing Cases. https://doi.org/10.1108/case.darden.2016.000103

Download as .RIS



University of Virginia Darden School Foundation

Copyright © 1988 by the University of Virginia Darden School Foundation, Charlottesville, VA. All rights reserved.

Please note you might not have access to this content

You may be able to access this content by login via Shibboleth, Open Athens or with your Emerald account.
If you would like to contact us about accessing this content, click the button and fill out the form.